Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.
about
Effectiveness of second generation antipsychotics: a systematic review of randomized trialsSecond-generation antipsychotics and extrapyramidal adverse effectsPharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for cliniciansBrain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicityToward a Hippocratic psychopharmacology.First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.The contribution of abdominal obesity and dyslipidemia to metabolic syndrome in psychiatric patients.Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth.Metformin and berberine prevent olanzapine-induced weight gain in ratsReduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapineGroup II metabotropic glutamate receptors and schizophrenia.Iloperidone: a new option for the treatment of schizophrenia.Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders.An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.Atypical antipsychotics and inverse agonism at 5-HT2 receptors.Glossopharyngeal Dystonia Secondary to a Lurasidone-Fluoxetine CYP-3A4 InteractionIncidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies.Examination of the role of dopamine D₂ and adrenergic α₂ receptors in resurgence of food seeking.Clozapine and cardiometabolic health in chronic schizophrenia: correlations and consequences in a clinical context.A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011.Assessment of novel iloperidone- and idebenone-loaded nanostructured lipid carriers: brain targeting efficiency and neuroprotective potential.Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.Interaction between the Val158Met catechol-O-methyltransferase gene variant and second-generation antipsychotic treatment on blood pressure in children.Oculogyric crisis with atypical antipsychotics: A case series.Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use.Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana
P2860
Q21260262-4B3F314A-CBBC-4DCE-A3E5-EBA3AEE56F68Q21284676-061687BE-A1C9-4B1C-8339-709CABD7EDF7Q24657338-FBE5D8A9-C330-400B-8E53-CD2042CA669CQ28394667-F8781AE3-A5ED-4C09-95A9-C494B3210312Q30369097-CA1EDBBF-1CE2-45A4-8FC2-6F00AEBB39C7Q33845881-613AEC0A-906B-412A-9BD5-3581961C64DFQ33893935-48426456-1E7E-4F72-99F1-F00A3CFAE02EQ34006864-FE26C427-BF2D-442F-85DE-E453FB52083FQ34900812-482C1059-33E1-4479-ACC9-6055F3D4C995Q35131343-3E3D9FBA-B70A-4086-8462-0F0CD43E56F0Q37233562-1A0E783B-5989-4514-8F75-DCEBC3754182Q37473779-DF26B9AA-8CA9-4BC9-B6E0-A2B19894A666Q37641995-7A8437D6-B949-463C-84FA-7CD1FE61DEF7Q37896627-D989AF7B-AD6E-4177-99C5-77BFF8B3A315Q38012489-93E78C54-9AFC-4742-9327-8296602A87F8Q39336646-90537263-0364-42B5-89ED-B25C85649F9CQ41250110-BA112F79-FFE5-4C06-BA92-B5FC6E61F92EQ41429342-AE499156-47FB-4DEE-8954-2BEF0CC4997FQ41862402-AEAB2D8F-43C8-4414-95FA-A0141835590AQ42767278-2B1EED04-16F1-4AC5-9A76-26DD3A99EAA3Q43205612-504B9CC8-4CBA-4449-85B1-274ABB848C44Q48461892-C5D508C5-C7C6-4E2C-8609-A297090D824CQ48873833-F22EADA3-CA33-46DD-A9E3-967B19AF1B92Q50737699-CA476A3B-444C-474C-A76A-B58605007B01Q51318568-252CE79F-70C1-4242-8C82-605486F44C9EQ51745529-5566EB20-D8A8-4239-9D9C-C322FF5CC08DQ53691732-9C59ED00-EB98-488C-B3C9-47F342C3E66CQ58969472-673DEF93-677B-4DFF-BB7E-2C610B1F51F9
P2860
Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Side effects of atypical antip ...... ms and the metabolic syndrome.
@ast
Side effects of atypical antip ...... ms and the metabolic syndrome.
@en
type
label
Side effects of atypical antip ...... ms and the metabolic syndrome.
@ast
Side effects of atypical antip ...... ms and the metabolic syndrome.
@en
prefLabel
Side effects of atypical antip ...... ms and the metabolic syndrome.
@ast
Side effects of atypical antip ...... ms and the metabolic syndrome.
@en
P1476
Side effects of atypical antip ...... ms and the metabolic syndrome.
@en
P2093
Arshia A Shirzadi
S Nassir Ghaemi
P304
P356
10.1080/10673220600748486
P577
2006-05-01T00:00:00Z